SRPT – Sarepta Therapeutics, Inc.
SRPT — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
24.9
Margin Of Safety %
23
Put/Call OI Ratio
0.84
EPS Next Q Diff
-2.38
EPS Last/This Y
11.96
EPS This/Next Y
-2.1
Price
16.81
Target Price
22.67
Analyst Recom
2.74
Performance Q
-7.28
Upside
-174.3%
Beta
0.22
Ticker: SRPT
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-23 | SRPT | 20.4 | 0.81 | 1.38 | 111821 |
| 2026-04-24 | SRPT | 20.27 | 0.84 | 1.14 | 116858 |
| 2026-04-27 | SRPT | 20.97 | 0.84 | 0.22 | 111439 |
| 2026-04-28 | SRPT | 21.05 | 0.82 | 0.26 | 112771 |
| 2026-04-29 | SRPT | 20.67 | 0.81 | 0.30 | 113755 |
| 2026-04-30 | SRPT | 20.88 | 0.81 | 0.21 | 114299 |
| 2026-05-01 | SRPT | 21.49 | 0.81 | 0.17 | 114584 |
| 2026-05-04 | SRPT | 22.03 | 0.81 | 0.32 | 110887 |
| 2026-05-05 | SRPT | 21.79 | 0.81 | 0.38 | 112655 |
| 2026-05-06 | SRPT | 22.88 | 0.80 | 1.02 | 113423 |
| 2026-05-07 | SRPT | 20.79 | 0.83 | 0.84 | 116476 |
| 2026-05-08 | SRPT | 19.96 | 0.83 | 0.11 | 117628 |
| 2026-05-11 | SRPT | 19.4 | 0.84 | 0.63 | 114241 |
| 2026-05-12 | SRPT | 19.12 | 0.84 | 0.26 | 114763 |
| 2026-05-13 | SRPT | 18.85 | 0.82 | 0.39 | 115261 |
| 2026-05-14 | SRPT | 18.67 | 0.81 | 0.68 | 115719 |
| 2026-05-15 | SRPT | 17.53 | 0.79 | 0.99 | 116167 |
| 2026-05-18 | SRPT | 17 | 0.87 | 0.71 | 103117 |
| 2026-05-19 | SRPT | 16.65 | 0.85 | 1.08 | 104014 |
| 2026-05-20 | SRPT | 17.11 | 0.85 | 0.72 | 105156 |
| 2026-05-21 | SRPT | 16.97 | 0.85 | 0.48 | 105848 |
| 2026-05-22 | SRPT | 16.81 | 0.84 | 0.85 | 105884 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-23 | SRPT | 20.41 | 130.6 | 783.1 | 4.14 |
| 2026-04-24 | SRPT | 20.27 | 130.6 | 782.3 | 3.99 |
| 2026-04-27 | SRPT | 20.98 | 130.6 | 786.3 | 3.99 |
| 2026-04-28 | SRPT | 21.07 | 130.6 | 787.4 | 3.99 |
| 2026-04-30 | SRPT | 20.87 | 130.6 | 786.3 | 3.99 |
| 2026-05-01 | SRPT | 21.48 | 130.6 | 789.8 | 3.99 |
| 2026-05-04 | SRPT | 22.03 | 130.6 | 792.8 | 3.99 |
| 2026-05-05 | SRPT | 21.79 | 130.6 | 791.5 | 3.99 |
| 2026-05-06 | SRPT | 23.03 | 130.6 | 799.9 | 3.99 |
| 2026-05-07 | SRPT | 20.79 | 130.6 | 785.9 | 3.99 |
| 2026-05-08 | SRPT | 19.95 | -47.2 | - | 3.92 |
| 2026-05-11 | SRPT | 19.41 | -47.2 | - | 3.92 |
| 2026-05-12 | SRPT | 19.13 | -72.2 | - | 3.92 |
| 2026-05-13 | SRPT | 18.85 | -72.2 | - | 3.92 |
| 2026-05-14 | SRPT | 18.67 | -72.2 | - | 3.92 |
| 2026-05-15 | SRPT | 17.54 | -72.2 | - | 4.82 |
| 2026-05-18 | SRPT | 17.01 | -72.2 | - | 4.82 |
| 2026-05-19 | SRPT | 16.65 | -72.2 | - | 4.82 |
| 2026-05-20 | SRPT | 17.13 | -75.8 | - | 4.83 |
| 2026-05-21 | SRPT | 16.95 | -75.8 | - | 4.83 |
| 2026-05-22 | SRPT | 16.81 | -75.8 | - | 4.83 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-23 | SRPT | -0.37 | -1.16 | 25.87 |
| 2026-04-24 | SRPT | -0.37 | -1.16 | 25.87 |
| 2026-04-27 | SRPT | -0.37 | -0.53 | 25.47 |
| 2026-04-28 | SRPT | -0.37 | -0.53 | 25.47 |
| 2026-04-29 | SRPT | -0.37 | -0.53 | 25.47 |
| 2026-04-30 | SRPT | -0.37 | -0.53 | 25.47 |
| 2026-05-01 | SRPT | -0.37 | -0.53 | 25.47 |
| 2026-05-04 | SRPT | -0.37 | -0.71 | 25.47 |
| 2026-05-05 | SRPT | -0.37 | -0.71 | 25.47 |
| 2026-05-06 | SRPT | -0.37 | -0.71 | 25.47 |
| 2026-05-07 | SRPT | -0.37 | -0.71 | 25.47 |
| 2026-05-08 | SRPT | -0.37 | -0.71 | 25.47 |
| 2026-05-11 | SRPT | -0.37 | -0.81 | 25.33 |
| 2026-05-12 | SRPT | -0.37 | -0.81 | 24.92 |
| 2026-05-13 | SRPT | -0.37 | -0.81 | 24.92 |
| 2026-05-14 | SRPT | -0.37 | -0.81 | 24.92 |
| 2026-05-15 | SRPT | -0.37 | -0.81 | 24.92 |
| 2026-05-18 | SRPT | -0.37 | -0.08 | 24.92 |
| 2026-05-19 | SRPT | -0.37 | -0.08 | 24.92 |
| 2026-05-20 | SRPT | -0.37 | -0.08 | 24.92 |
| 2026-05-21 | SRPT | -0.37 | -0.08 | 24.90 |
| 2026-05-22 | SRPT | -0.37 | -0.08 | 24.90 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
2.88
Avg. EPS Est. Current Quarter
0.49
Avg. EPS Est. Next Quarter
0.5
Insider Transactions
-0.37
Institutional Transactions
-0.08
Beta
0.22
Average Sales Estimate Current Quarter
361
Average Sales Estimate Next Quarter
367
Fair Value
20.75
Quality Score
66
Growth Score
35
Sentiment Score
10
Actual DrawDown %
90.3
Max Drawdown 5-Year %
-92.7
Target Price
22.67
P/E
Forward P/E
17.67
PEG
P/S
0.81
P/B
1.18
P/Free Cash Flow
18.13
EPS
-0.96
Average EPS Est. Cur. Y
4.83
EPS Next Y. (Est.)
2.73
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-2.94
Relative Volume
0.64
Return on Equity vs Sector %
-22.7
Return on Equity vs Industry %
-7.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.84
EBIT Estimation
◆
SRPT
Healthcare
$16.80
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
32.7
Range 1M
3.4%
Sup Dist
0.8%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
148.5%
EPS NY
-72.5%
52W%
19.1%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+69.7% upside
Upside
+69.7%
Quality
66
MoS
23%
Sarepta Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 835
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
SRPT
Latest News
—
Caricamento notizie per SRPT…
stock quote shares SRPT – Sarepta Therapeutics, Inc. Stock Price stock today
news today SRPT – Sarepta Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch SRPT – Sarepta Therapeutics, Inc. yahoo finance google finance
stock history SRPT – Sarepta Therapeutics, Inc. invest stock market
stock prices SRPT premarket after hours
ticker SRPT fair value insiders trading